Annovis Bio, Inc.(NYSE Amex Equities : ANVS)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-1.60%||162.57||0.7%||$1033.19m|
|MRK||Merck & Co., Inc.||-0.65%||76.73||0.7%||$981.19m|
|LLY||Eli Lilly & Co.||-1.18%||219.60||1.1%||$901.61m|
|BMY||Bristol-Myers Squibb Co.||-0.63%||66.35||1.0%||$618.54m|
|ANVS||Annovis Bio, Inc.||3.09%||92.83||0.0%||$315.87m|
|BTX||Brooklyn ImmunoTherapeutics, Inc.||12.09%||17.20||12.4%||$106.49m|
|CNST||Constellation Pharmaceuticals, Inc.||-0.27%||33.73||0.0%||$104.56m|
Annovis Bio, Inc. is a clinical stage drug platform company, which develops drugs to treat neurodegeneration. The firm compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also develops ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.